* Eledon Pharmaceuticals Inc reported a quarterly adjusted loss of 32 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of five analysts for the quarter was for a loss of 31 cents per share. Wall Street expected results to range from -37 cents to -20 cents per share.
* Reported revenue was zero; analysts expected zero.
* Eledon Pharmaceuticals Inc's reported EPS for the quarter was a loss of 32 cents.
* The company reported a quarterly loss of $17.5 million.
* Eledon Pharmaceuticals Inc shares had risen by 99.2% this quarter and gained 175.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 14.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $10.00 This summary was machine generated from LSEG data November 12 at 11:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.31 -0.32 Missed
Jun. 30 2024 -0.30 -1.06 Missed
Mar. 31 2024 -0.37 -0.34 Beat
Dec. 31 2023 -0.39 -0.29 Beat
Comments